An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)

PHASE3CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

November 4, 2024

Study Completion Date

July 25, 2025

Conditions
Thyroid Eye Disease
Interventions
DRUG

Veligrotug (VRDN-001)

Veligrotug (VRDN-001) is a humanized monoclonal antibody directed against the IGF-1 receptor

DRUG

Placebo

5 IV infusions of placebo

Trial Locations (57)

2065

North Shore Private Hospital, Saint Leonards

13353

Charité - Universitätsmedizin Berlin KöR, Berlin

14012

Hospital La Arruzafa, Córdoba

15706

Complexo Hospitalario Universitario de Santiago-Hospital Médico-Cirúrxico de Conxo, A Coruña

19104

Department of Ophthalmology, University of Pennsylvania, Philadelphia

19107

Wills Eye Hospital, Philadelphia

28034

Hospital Universitario Ramón y Cajal, Madrid

33000

CHU de Bordeaux - Hôpital Saint-André, Bordeaux

33136

Bascom Palmer Eye Institute - Ophthalmology - Miami, Miami

34239

Sarasota Retina Institute, Sarasota

34854

Marmara University Faculty of Medicine, Istanbul

37075

Universitätsmedizin Göttingen, Göttingen

41009

Hospital Universitario Virgen De La Macarena, Seville

41013

Hospital Universitario Virgen del Rocio, Seville

44093

Centre Hospitalier Universitaire De Nantes - G. R. Laennec, Nantes

45122

Universitätsklinikum Essen AöR, Essen

46026

Hospital Universitario Y Politécnico La Fe, Valencia

48152

Kahana Oculoplastic and Orbital Surgery, Livonia

48824

Michigan State University, Department of Neurology, East Lansing

49033

CHU Angers, Angers

50009

Hospital Unviersitario Miguel Servet, Zaragoza

60453

Family Eye Physicians, Ltd, Oak Lawn

60611

Northwestern University, Chicago

63110

Washington University School of Medicine in St Louis - Ophthalmology, St Louis

77030

Baylor College of Medicine (BCM) - Ophthalmology, Houston

77074

Neuro Eye Clinical Trials, Houston

79106

University Medical Center Freiburg, Freiburg im Breisgau

89144

Steven Leibowitz, MD., Las Vegas

90023

Advancing Research International, LLC, Los Angeles

90089

USC Roski Eye Institute, Los Angeles

92108

Cockerham Eye Consultants, PC, San Diego

92660

Amy Patel Jain, MD, Newport Beach

94303

Stanford Byers Eye Institute, Palo Alto

98104

Harborview Medical Center, Seattle

02114

Massachusetts Eye and Ear, Boston

02189

Ophthalmic Consultants of Boston, Boston

07103

Rutgers - New Jersey Medical School, Newark

08873

The Center for Eye and Facial Plastic Surgery, Somerset

05401

University of Vermont Medical Center, Burlington

06000

CH Nice, Nice

H-1133

Budapest Retina Intezet, Budapest

H-7621

Ganglion Orvosi Kozpont, Pécs

H-7623

Pecsi Tudomanyegyetem Klinikai Kozpont Szemeszeti Klinika, Pécs

15-276

Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok

85-157

Oculomedica Sp. z o.o., Bialystok

80-809

Optimum Profesorskie Centrum Okulistyki Sp. z o.o., Gdansk

05-500

Centrum Medyczne Pulawska Sp. z o.o., Piaseczno

58-304

Centrum Medyczne Piasta 47 sp. z o.o., Wałbrzych

08021

Centro de Oftalmologia Barraquer (Barraquer Ophthalmology Centre), Barcelona

06230

Hacettepe Universitesi Tip Fakultesi, Ankara

06500

Gazi University Medical Faculty Hospital, Ankara

07059

Akdeniz University Medical Faculty Hospital, Antalya

EC1V 2PD

Moorfield's Eye Hospital, London

NW1 5QH

Imperial College Healthcare NHS Trust - Western eye Hospital, London

SE1 7EH

Guy's and St. Thomas NHS Trust, London

NEI 4LP

The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle

SO16 6YD

University Hospital Southampton NHS Foundation Trust, Southampton

All Listed Sponsors
lead

Viridian Therapeutics, Inc.

INDUSTRY

NCT06021054 - An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2) | Biotech Hunter | Biotech Hunter